<DOC>
	<DOCNO>NCT00544024</DOCNO>
	<brief_summary>The objective study determine bioequivalence among three commercial tablet formulation MQ , i.e . Lariam , Mephaquin , Mefloquine- ( AC Farma ) give combination artesunate .</brief_summary>
	<brief_title>Mefloquine Bioequivalence Among 3 Commercially Available Tablets .</brief_title>
	<detailed_description>Pharmacokinetic parameter determine mefloquine whole blood Peruvian subject uncomplicated falciparum malaria administer Mephaquin® , Mefloquine-AC Farma , Lariam® . The Mefloquine-AC Farma arm comprise 13 patient reference ( Lariam ) Mephaquin arm consist 12 patient . Although Cmax significantly less ( p=0.04 ) Mephaquin arm ( AUC0-t = 2500 ng/ml/day ) relative reference ( AUC0-t = 2820 ng/ml/day ) arm , significant difference AUC∞ , tmax , t1/2 Mefloquine-AC Farma Mephaquin relative reference . Except Cmax Mefloquine-AC Farma , 90 % confidence interval parameter treatment outside specified FDA range 80-125 % . Therefore formulation consider bioequivalent reference .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>The inclusion criterion enrol patient include ; male nonpregnant female ≥ 18 year age , infection P. falciparum alone , parasite density 250 50,000 asexual parasites/mm3 determine microscopic examination thick blood smear , informed consent patient , willingness hospitalize first 24 hour therapy initiate return followup visit day 56 . Patients exhibit evidence severe malaria history underlie chronic disease illness could interfere absorption MQ , history hypersensitivity MQ , history neuropsychiatric illness cardiac conduction problem exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Mefloquine</keyword>
</DOC>